Anti–tumor necrosis factor (TNF) agents, widely used in rheumatology and gastroenterology, carry some safety risks. While the risk of infection or malignancy are common concerns, neurological complications, while rare, are also possible.
Anti—tumor necrosis factor (anti-TNF) agents, widely used in rheumatology and gastroenterology, carry some safety risks. While the risk of infection or malignancy are common concerns, neurological complications, while rare, are also possible.
During the fourth congress of the European Academy of Neurology, held in Lisbon, Portugal, from June 16 to 19, researchers reported on neurological complications with anti-TNF drugs in their 16 years of experience in a tertiary university hospital in Madrid, Spain.
The researchers performed a retrospective analysis of their center’s neurology department from 2002 to 2007 and identified patients who had received the anti-TNF agents infliximab, etanercept, adalimumab, and golimumab. They included in their analysis patients who had neurological issues while actively being treated with any of these agents.
In total, there were 15 episodes of neurological complications in 14 patients who were receiving treatment with infliximab, adalimumab, or golimumab to treat inflammatory bowel disease, rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, or pyoderma gangrenosum. No patients being treated with etanercept reported neurological complications.
Nine of the patients who had complications were treated with infliximab, 6 were treated with adalimumab, and 1 was treated with golimumab.
In total:
The authors write that, in their experience, neurological complications of anti-TNF therapies are rare, but that they are most commonly reported with infliximab, and stroke is the most commonly reported complication; “A possible association with stroke of undetermined etiology should be assessed with prospective studies,” say the researchers.
Reference
Gomez A, Nater E, Monreal S, et al. Neurological complications of antiTNF therapies: 16 years of tertiary university hospital experience. Presented at the European Academy of Neurology Congress, June 16-19, 2018; Lisbon, Portugal. Abstract EPR1130. https://ipp-ean18.netkey.at/index.php?p=recorddetail&rid=2dec48c7-efbe-4a30-aa16-a7c040870eb3&t=browsepresentations.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.